Search results for "Photochemotherapy"

showing 10 items of 60 documents

A randomized, intraindividual, non-inferiority, Phase III study comparing daylight photodynamic therapy with BF-200 ALA gel and MAL cream for the tre…

2018

Abstract Background The most effective treatment modality for actinic keratosis (AK) is photodynamic therapy (PDT). Major obstacles of PDT are the need of a special illumination device and pain accompanying the illumination. These issues may be overcome by replacing an artificial high‐power light source with natural daylight for more extended illumination at lower light doses. Objective To determine whether BF‐200 ALA (a nanoemulsion gel containing 7.8% 5‐aminolaevulinic acid) is non‐inferior to MAL (a cream containing 16% methyl‐aminolaevulinate) in the treatment of mild‐to‐moderate AK with daylight PDT (dPDT). Non‐inferiority of the primary efficacy variable (total lesion clearance rate p…

Malemedicine.medical_specialtyKeratosisgenetic structuresOriginal Articles and Short Reports Oncologymedicine.medical_treatmentUrologySkin CreamPhotodynamic therapyDermatologyAdministration CutaneousSeverity of Illness IndexStatistics Nonparametriclaw.inventionLesion030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled triallawGermanySeverity of illnessmedicineClinical endpointHumansAgedPhotosensitizing Agentsbusiness.industryActinic keratosisAminolevulinic Acidmedicine.diseasePrognosisClinical trialKeratosis ActinicInfectious DiseasesTreatment OutcomePhotochemotherapySpain030220 oncology & carcinogenesisFemaleOriginal Articlemedicine.symptombusinessGelsJournal of the European Academy of Dermatology and Venereology : JEADV
researchProduct

PHOTODYNAMIC THERAPY WITH VERTEPORFIN FOR CHOROIDAL NEOVASCULARIZATION ASSOCIATED WITH RETINAL PIGMENT EPITHELIAL DETACHMENT IN AGE-RELATED MACULAR D…

2007

Abstract PURPOSE: To assess the effectiveness of photodynamic therapy (PDT) with verteporfin for choroidal neovascularization (CNV) associated with retinal pigment epithelium detachment (PED) in age-related macular degeneration. METHODS: Thirty eyes of 26 patients with CNV and PED were treated with PDT. The eyes were divided in two groups based on CNV location in relation to PED; group 1 included 13 eyes with CNV within PED, and group 2 included 17 eyes with CNV at the edge of PED. The median follow-up was 16 months. RESULTS: Patients received a mean +/- SD of 2.83 +/- 1.26 treatments (range, 1-6 treatments). In the whole cohort, the mean preoperative visual acuity changed from 20/144 (0.86…

Malemedicine.medical_specialtyPorphyrinsVisual acuitygenetic structuresmedicine.medical_treatmentVisual AcuityPhotodynamic therapyMacular DegenerationAge relatedOphthalmologymedicineHumansProspective StudiesFluorescein AngiographyPigment Epithelium of EyeAgedAged 80 and overPhotosensitizing AgentsRetinal pigment epitheliumSettore MED/30 - Malattie Apparato Visivobusiness.industryRetinal DetachmentVerteporfinGeneral MedicineMiddle AgedMacular degenerationmedicine.diseaseVerteporfinChoroidal Neovascularizationeye diseasesOphthalmologyTreatment Outcomemedicine.anatomical_structureChoroidal neovascularizationPhotochemotherapyFemaleRetinal pigment epithelial detachmentsense organsPhotodynamic therapy choroidal neovascularization age-related macular degenerationmedicine.symptombusinessFollow-Up Studiesmedicine.drugRetina
researchProduct

Clinical Outcome and Subjective Quality of Life after Photodynamic Therapy in Patients with Age-Related Macular Degeneration

2005

PURPOSE. Whereas the efficacy of photodynamic therapy (PDT) in preventing the progression of age-related macular degeneration (ARMD) is established, its effect on quality of life is under discussion. METHODS. All patientswho underwent PDT during 2000 and 2001 at the University Eye Hospital of Mainz were interviewed using a standardized 82-item questionnaire on quality of life and patient satisfaction in ophthalmologic patients. Information was assessed in terms of 82 questions; global scores ranging from 1.0 (optimum self-estimated quality of life) to 4.0 (worst) were derived. Cataract patients' scores were used to characterize the ARMD patients' subjective outcome; the latter were then rel…

Malemedicine.medical_specialtyPorphyrinsVisual acuitymedicine.medical_treatmentVisual AcuityPsychological interventionPhotodynamic therapyLogistic regressionMacular Degeneration03 medical and health sciences0302 clinical medicinePatient satisfactionQuality of lifeSurveys and QuestionnairesInternal medicineActivities of Daily LivingmedicineHumansIn patientAgedRetrospective StudiesAged 80 and overPhotosensitizing Agentsbusiness.industryVerteporfinGeneral MedicineMacular degenerationmedicine.diseaseChoroidal Neovascularizationeye diseasesOphthalmologyCross-Sectional StudiesTreatment OutcomePhotochemotherapyPatient SatisfactionQuality of Life030221 ophthalmology & optometryPhysical therapyFemalemedicine.symptombusiness030217 neurology & neurosurgeryEuropean Journal of Ophthalmology
researchProduct

Back pain after photodynamic therapy with verteporfin.

2005

Purpose To report the incidence of back pain after photodynamic therapy, which suggests methods for prevention that are related to its pathogenesis. Design Retrospective case series. Methods We retrospectively observed 548 patients who had undergone photodynamic therapy with verteporfin. Results Of 548 patients at the first treatment, 14 patients (2.6%) experienced pain during the infusion. Eleven patients were being treated for age-related macular degeneration; their mean age was 81 years, which significantly differed from the mean age of the overall age-related macular degeneration group ( P = .003). The pain was mild in eight patients, moderate in four patients, and severe in two patient…

Malemedicine.medical_specialtyPorphyrinsmedicine.medical_treatmentPhotodynamic therapyMacular Degenerationback painphotodynamic therapymedicineBack painHumansInfusions IntravenousAgedRetrospective StudiesAged 80 and overPhotosensitizing AgentsMild painSettore MED/30 - Malattie Apparato Visivobusiness.industryIncidence (epidemiology)IncidenceVerteporfinRetrospective cohort studyMacular degenerationMiddle Agedmedicine.diseaseVerteporfinLow back painChoroidal NeovascularizationSurgeryOphthalmologyPhotochemotherapyBack PainMyopia DegenerativeFemalemedicine.symptombusinessmedicine.drugAmerican journal of ophthalmology
researchProduct

A randomized, multinational, noninferiority, phase III trial to evaluate the safety and efficacy of BF-200 aminolaevulinic acid gel vs. methyl aminol…

2018

Background: Basal cell carcinoma (BCC) represents the most common nonmelanoma skin cancer worldwide, affecting mainly adult, fair-skinned individuals. The World Health Organization distinguishes aggressive and nonaggressive forms, of which prototypical variants of the latter are primary nodular and superficial BCC. Objective: To demonstrate noninferiority of BF-200 ALA (a nanoemulsion gel containing 5-aminolaevulinic acid) compared with MAL (a cream containing methyl aminolaevulinate) in the treatment of nonaggressive BCC with photodynamic therapy (PDT). Noninferiority of the primary efficacy variable (overall patient complete response 12 weeks after last PDT) would be declared if the mean …

Malemedicine.medical_specialtySkin Neoplasmsmedicine.medical_treatmentSkin CreamPhotodynamic therapyDermatologyAdministration Cutaneouslaw.invention030207 dermatology & venereal diseases03 medical and health sciences0302 clinical medicineRandomized controlled trialMethyl aminolevulinatelawCarcinomaHumansMedicineBasal cell carcinomaAgedSkinPhotosensitizing Agentsbusiness.industryActinic keratosisAminolevulinic AcidMiddle Agedmedicine.diseaseDermatologyClinical trialTreatment OutcomePhotochemotherapyCarcinoma Basal Cell030220 oncology & carcinogenesisFemaleSkin cancerbusinessmedicine.drugBritish Journal of Dermatology
researchProduct

Long-term results of photodynamic therapy with 5-aminolevulinic acid for superficial Barrett's cancer and high-grade intraepithelial neoplasia

2005

Photodynamic therapy (PDT) with 5-aminolevulinic acid (ALA) has proven to be safe and effective in patients with early neoplasia in Barrett's esophagus. However, long-term results in patients with high-grade intraepithelial neoplasia (HGIN) or with early cancer are still lacking.The aim of the study was to evaluate the efficacy of ALA-PDT and the survival of patients with early Barrett's neoplasia. ALA-PDT was carried out in 66 patients. Protoporphyrin IX induced by oral administration of ALA (60 mg/kg body weight orally applied 4-6 hours before PDT) was used as the photosensitizer. Acid suppression was maintained in all patients.Between September 1996 and September 2002, 667 patients with …

Malemedicine.medical_specialtyTime FactorsEsophageal Neoplasmsmedicine.medical_treatmentPhotodynamic therapyAdenocarcinomaSeverity of Illness IndexGastroenterologyDisease-Free SurvivalBarrett EsophagusGermanyInternal medicineHumansMedicineRadiology Nuclear Medicine and imagingEsophagusSurvival rateAgedNeoplasm StagingRetrospective StudiesIntraepithelial neoplasiaPhotosensitizing Agentsbusiness.industryGastroenterologyCancerAminolevulinic AcidMiddle Agedmedicine.diseaseSurvival RateTreatment Outcomemedicine.anatomical_structurePhotochemotherapyEsophagectomyHigh Grade Intraepithelial NeoplasiaAdenocarcinomaFemalebusinessPrecancerous ConditionsFollow-Up StudiesGastrointestinal Endoscopy
researchProduct

Near-infrared photochemistry assisted by upconverting nanoparticles

2019

Abstract Upconverting nanoparticles (UCNPs) combine unique optical and imaging properties with high chemical and biological stability. The capability of UCNPs to emit visible light upon near-infrared light excitation, in an anti-Stokes fashion, is extremely attractive for the design of light-responsive nanomaterials whose action can be controlled spatially and temporally. In this chapter, we analyze the most promising approaches developed so far to functionalize the surface of UCNPs with photoactivatable organic and inorganic molecular systems. In particular, we emphasize the key advances in the design of upconverting nanosystems that exploit bioactive transition metal complexes.

Materials sciencePhotochemistryNear infraredNear-infrared spectroscopyOrganic chemistryNanotechnologyMolecular systemsCoordination chemistryNanomaterialsPhotochemotherapySettore CHIM/03 - Chimica Generale E InorganicaUpconverting nanoparticlesLanthanidesProdrugsLight excitationUpconverting nanoparticlesVisible spectrum
researchProduct

Double-Network-Structured Graphene Oxide-Containing Nanogels as Photothermal Agents for the Treatment of Colorectal Cancer.

2017

Here, we reported the production of hyaluronic acid/polyaspartamide-based double-network nanogels for the potential treatment of colorectal carcinoma. Graphene oxide, thanks to the huge aromatic surface area, allows to easily load high amount of irinotecan (33.0% w/w) and confers to the system hyperthermic properties when irradiated with a near-infrared (NIR) laser beam. We demonstrate that the release of antitumor drug is influenced both by the pH of the external medium and the NIR irradiation process. In vitro biological studies, conducted on human colon cancer cells (HCT 116), revealed that nanogels are uptaken by the cancer cells and, in the presence of the antitumor drug, can produce a…

Models MolecularPolymers and PlasticsColorectal cancerInfrared RaysProtein ConformationNanogelsBioengineeringNanotechnologyAntineoplastic Agents02 engineering and technology010402 general chemistry01 natural scienceslaw.inventionPolyethylene GlycolsBiomaterialschemistry.chemical_compoundgraphene oxide hydrogel nenogel cancer therapylawHyaluronic acidMaterials ChemistrymedicineCytotoxic T cellHumansPolyethyleneimineHyaluronic AcidGrapheneChemistryOxidesPhotothermal therapy021001 nanoscience & nanotechnologymedicine.diseaseHCT116 CellsIn vitro0104 chemical sciencesIrinotecanPhotochemotherapyCancer cellCancer researchGraphite0210 nano-technologyColorectal Neoplasmsmedicine.drugBiomacromolecules
researchProduct

Progress of Phototherapy Applications in the Treatment of Bone Cancer

2021

Bone cancer including primary bone cancer and metastatic bone cancer, remains a challenge claiming millions of lives and affecting the life quality of survivors. Conventional treatments of bone cancer include wide surgical resection, radiotherapy, and chemotherapy. However, some bone cancer cells may remain or recur in the local area after resection, some are highly resistant to chemotherapy, and some are insensitive to radiotherapy. Phototherapy (PT) including photodynamic therapy (PDT) and photothermal therapy (PTT), is a clinically approved, minimally invasive, and highly selective treatment, and has been widely reported for cancer therapy. Under the irradiation of light of a specific wa…

Oncologymedicine.medical_specialtyQH301-705.5Photothermal Therapymedicine.medical_treatmentCancer therapyBone NeoplasmsPhotodynamic therapyReviewCatalysisInorganic ChemistryInternal medicineHumansMedicineBiology (General)Physical and Theoretical ChemistryQD1-999Molecular BiologySpectroscopyOsteosarcomaChemotherapyPhotosensitizing Agentsbusiness.industryBone cancerOrganic ChemistryCancerbone cancerGeneral MedicinePhototherapyPhotothermal therapymedicine.diseaseComputer Science ApplicationsRadiation therapyChemistryPrimary bonephotodynamic therapyPhotochemotherapyNanoparticlesGoldtumor therapyNeoplasm Recurrence LocalReactive Oxygen SpeciesbusinessInternational Journal of Molecular Sciences
researchProduct

Polypoidal choroidal vasculopathy in pachychoroid: combined treatment with photodynamic therapy and aflibercept

2022

Abstract Introduction To evaluate the effects of combined therapy using intravitreal Aflibercept (IVA) and photodynamic therapy (PDT) on polypoidal choroidal vasculopathy related to pachychoroid disease (PPCV).Methods Patients with PPCV were treated with PDT combined with 3 IVA injections on a monthly basis, followed by pro re nata criteria. The 12-month follow-up consisted of multiple revaluations of visual acuity and SSOCT parameters of clinical activity.Results Nineteen eyes were included in the study; mean age was 65.5 years. Visual acuity improved after 12 months (0.35 ± 0.25 to 0.2 ± 0.20 logMAR, p = 0.005). Percentage of eyes with intraretinal and subretinal fluid reduced from baseli…

Oncologymedicine.medical_specialtygenetic structuresRecombinant Fusion Proteinsmedicine.medical_treatmentAngiogenesis InhibitorsPhotodynamic therapyPhotodynamic therapyCombined treatmentInternal medicinePolypoidal choroidal vasculopathyHumansMedicinePachychoroidFluorescein AngiographyAgedRetrospective StudiesAfliberceptbusiness.industryeye diseasesOphthalmologyReceptors Vascular Endothelial Growth FactorTreatment OutcomePhotochemotherapyIntravitreal InjectionsbusinessAfliberceptSwept Source OCTTomography Optical Coherencemedicine.drugInternational Ophthalmology
researchProduct